THE POTENTIAL TO IMPROVE INHALATION TECHNIQUE IN PATIENTS WITH ASTHMA OR COPD BY SWITCHING FROM SYMBICORT® TURBUHALER® (BUDESONIDE + FORMOTEROL) TO DUORESP® SPIROMAX®- ESTIMATED IMPACT ON THE NUMBER AND COST OF UNSCHEDULED HEALTHCARE EVENTS ...

Author(s)

Watson A1, Bijos P2, Ludwikowski R2, Lewis A1, Blackney M1, Torvinen S3, Plich A3
1Covance Market Access, London, UK, 2Teva Pharmaceuticals Polska, Warszawa, Poland, 3Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

OBJECTIVES:  DuoResp® Spiromax® is a dry powder inhaler delivering a fixed-dose combination of budesonide + formoterol for the treatment of adults with asthma or chronic obstructive pulmonary disease (COPD). Post-hoc analysis of the ELIOT trial – a parallel-group, open-label study – showed that significantly fewer people using DuoResp® Spiromax® had poor inhalation technique compared with Symbicort® Turbuhaler®

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PMD22

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×